Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $39.32

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average rating of “Hold” by the seventeen analysts that are presently covering the firm, MarketBeat reports. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $39.3214.

Several analysts recently commented on HIMS shares. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. TD Cowen cut their price objective on Hims & Hers Health from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Monday, February 9th. Bank of America decreased their price objective on Hims & Hers Health from $26.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, February 9th. Citigroup dropped their target price on shares of Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating on the stock in a report on Monday, February 9th. Finally, KeyCorp initiated coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company.

Hims & Hers Health Trading Up 3.2%

Shares of NYSE HIMS opened at $16.31 on Friday. Hims & Hers Health has a twelve month low of $15.63 and a twelve month high of $72.98. The stock has a market cap of $3.71 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 3.04 and a beta of 2.43. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The company’s fifty day moving average is $30.41 and its 200-day moving average is $41.46.

Hims & Hers Health declared that its Board of Directors has authorized a share buyback program on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Chi sold 13,750 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 82,963 shares of company stock worth $2,944,621. 17.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC boosted its holdings in Hims & Hers Health by 4.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,059 shares of the company’s stock worth $521,000 after purchasing an additional 756 shares during the last quarter. MML Investors Services LLC boosted its stake in shares of Hims & Hers Health by 209.9% during the 4th quarter. MML Investors Services LLC now owns 51,616 shares of the company’s stock worth $1,676,000 after buying an additional 34,958 shares during the last quarter. Clear Street Group Inc. grew its holdings in shares of Hims & Hers Health by 23.6% in the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock valued at $61,832,000 after acquiring an additional 363,893 shares in the last quarter. CreativeOne Wealth LLC grew its holdings in shares of Hims & Hers Health by 6.6% in the 4th quarter. CreativeOne Wealth LLC now owns 30,745 shares of the company’s stock valued at $998,000 after acquiring an additional 1,909 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $204,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.